IMARC Group, a leading market research company, has recently releases report titled “Oncology Based In-vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global oncology based in-vivo CRO market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How Big is the Oncology Based In-vivo CRO Market?

The global oncology based in-vivo CRO market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.8 Billion by 2028, exhibiting a growth rate (CAGR) of 7.65% during 2023-2028.

Oncology is a medical field that focuses on the diagnosis, treatment, and study of cancer. It uses diagnostic tools such as biopsy, X-rays, CT scans, MRI, PET scans, endoscopy, and ultrasound to identify and examine the disease. It offers various therapeutic options for patients to manage and alleviate the side effects of cancer, including hormonal therapy, immunotherapy, radiotherapy, and oral treatments. Currently, oncology based in-vivo CRO is gaining immense traction across the globe due to the advancements made by contract research organizations (CROs) in developing new cancer treatments.

Request Free Sample Copy of This Report: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample

What are the growth prospects and trends in the oncology based in-vivo CRO industry?

The global oncology based in-vivo CRO market is primarily driven by the rising prevalence of cancer. Moreover, the increasing use of genetic engineering techniques to alter the characteristics of organisms and the rising focus on the study of oncogenes to regulate cell growth, differentiation, and proliferation are positively influencing market growth.

Additionally, the cost-effectiveness of CROs compared to in-house studies is another major growth-inducing factor. Furthermore, the surging adoption of telehealth and virtual clinical trials in the healthcare sector for ensuring the safety of cancer patients is propelling the market growth.

Other factors, including rising investments in research and development (R&D) activities, easy availability of medicines, and rapid expansion in the healthcare industry, are also anticipated to create a positive market outlook.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Indication:

• Blood Cancer

• Solid Tumors

• Others

Breakup by Model:

• Syngeneic

• Xenograft

• Patient Derived Xenograft (PDX)

• Others

Breakup by Application:

• Hospitals

• Rehabilitation Centers

Breakup by Region:

• North America: (United States, Canada)

• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America: (Brazil, Mexico, Others)

• Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including: 

Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/